Company Analysis

LeonaBio, Inc. (LONA)

Nasdaq: LONA · Biological Products, (No Diagnostic Substances) · Bothell, WA · filing with the SEC since 2014
Grade5.3
◀ Past 5.4● Present 4.4▶ Future 6.0
6 est.
The companyfiscal 2025, as filed
Revenuen/a
Net income-$106M-8.9%
Earnings per share$-24.70+1.9%
Operating cash flow-$45.7M+52.9%
Cash$69.3M+43.0%
Debtn/a
Shareholders’ equity$27.8M-38.0%
Shares, diluted4,275,762+11.1%
Return on equity-380.0%
The recordfrom its filings
Filings in 202687
Newest filingNov 4 · SCHEDULE 13G
Annual reportMar 31, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents granted3
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$141MCash from operations -$61.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Oct 28, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 26, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 22, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 31, 2026 · SEC EDGAR · Form SCHEDULE 13D
Activist holder notice
Open the filing on sec.gov
Aug 26, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton LONA · research, not advice